Free access to Elaprase
Tuesday, 02 September, 2008
The Hunter syndrome drug Elaprase, marketed by Genzyme Australasia, will be funded by the federal government under its life saving drugs program.
Hunter syndrome, or Mucopolysaccharidosis II, is a rare inherited enzyme disorder is caused by a deficiency in the iduronate-2-sulfatase enzyme, which is necessary for recycling certain complex carbohydrates.
Symptoms can include joint stiffness, breathing difficulties, heart problems, enlargement of the spleen an liver and skeletal deformities.
Elaprase replaces the missing enzyme needed to break down these complex carbohydrates.
Genzyme will continue providing free access to the treatment to two Hunter syndrome patients until it becomes government-funded on December 1.
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
